Major depression disorder (MDD) is a significant health problem with a prevalence of approximately 25% in multiple sclerosis (MS).Reference Young, Langdon and Rog1 Existing treatments for MDD in persons with MS are primarily neuropharmacological, with emerging research investigating repetitive transcranial magnetic stimulation (rTMS), an established treatment method for MDD in the general population. The present work continues the ongoing discussion seeking to evaluate the optimal therapeutic neurostimulation method between intermittent theta burst stimulation (iTBS) and rTMS (e.g., 10 Hz rTMS).Reference Scho, Brüchle, Schneefeld and Rosenkranz2,Reference Blumberger, Vila-Rodriguez and Thorpe3 iTBS is performed for a shorter duration than 10 Hz rTMS (approximately 3 min vs. 30–40 min, respectively, though shorter versions of rTMS have been proposed),Reference Scho, Brüchle, Schneefeld and Rosenkranz2
potentially making iTBS a more tolerable option for patients.
Giacobbe et al. present an open-label trial in 17 participants investigating the use of intermittent theta burst stimulation iTBS for the treatment of MDD in patients with multiple sclerosis.Reference Giacobbe, Bennett and Nestor4 It presents promising results, which would support a future randomised sham-controlled trial to address the present study limitations of sample size in addition to a lack of sham control and blinding. The findings expand on the applications of iTBS in a meaningful way, and results are congruent with previous research, which supports iTBS as a potential alternative to rTMS.Reference Blumberger, Vila-Rodriguez and Thorpe3
Across the 17 participants, ten responded (59%), of whom seven (41% of the total sample) remitted following iTBS. This rate of 10:7 (responders:non-responders) is consistent with previous literatureReference Blumberger, Vila-Rodriguez and Thorpe3 and may outperform rates observed following rTMS.Reference McClintock, Reti and Carpenter5 While impressive, future research with the primary objective of understanding and detecting non-responders early in the treatment protocol is suggested, given that 41% of patients are non-responders. At a therapeutic scale, early detection and cessation of treatment protocols on non-responders reduces unnecessary risk to patients and alleviates the burden on the medical system.
In responders, the results are remarkable and include improvements in both depression and cognition. These outcomes are promising, but knowing the full impact requires understanding the long-term behaviour of the effects. Importantly, these improvements were obtained with slightly more than a total of one hour of iTBS exposure across 4 weeks, approximately ten times less than would be required for an rTMS treatment. Future work should more rigorously investigate these findings through randomised controlled trials, including assessment of long-term cognitive outcomes and risk of dementia.
Major depression disorder (MDD) is a significant health problem with a prevalence of approximately 25% in multiple sclerosis (MS).Reference Young, Langdon and Rog1 Existing treatments for MDD in persons with MS are primarily neuropharmacological, with emerging research investigating repetitive transcranial magnetic stimulation (rTMS), an established treatment method for MDD in the general population. The present work continues the ongoing discussion seeking to evaluate the optimal therapeutic neurostimulation method between intermittent theta burst stimulation (iTBS) and rTMS (e.g., 10 Hz rTMS).Reference Scho, Brüchle, Schneefeld and Rosenkranz2,Reference Blumberger, Vila-Rodriguez and Thorpe3 iTBS is performed for a shorter duration than 10 Hz rTMS (approximately 3 min vs. 30–40 min, respectively, though shorter versions of rTMS have been proposed),Reference Scho, Brüchle, Schneefeld and Rosenkranz2 potentially making iTBS a more tolerable option for patients.
Giacobbe et al. present an open-label trial in 17 participants investigating the use of intermittent theta burst stimulation iTBS for the treatment of MDD in patients with multiple sclerosis.Reference Giacobbe, Bennett and Nestor4 It presents promising results, which would support a future randomised sham-controlled trial to address the present study limitations of sample size in addition to a lack of sham control and blinding. The findings expand on the applications of iTBS in a meaningful way, and results are congruent with previous research, which supports iTBS as a potential alternative to rTMS.Reference Blumberger, Vila-Rodriguez and Thorpe3
Across the 17 participants, ten responded (59%), of whom seven (41% of the total sample) remitted following iTBS. This rate of 10:7 (responders:non-responders) is consistent with previous literatureReference Blumberger, Vila-Rodriguez and Thorpe3 and may outperform rates observed following rTMS.Reference McClintock, Reti and Carpenter5 While impressive, future research with the primary objective of understanding and detecting non-responders early in the treatment protocol is suggested, given that 41% of patients are non-responders. At a therapeutic scale, early detection and cessation of treatment protocols on non-responders reduces unnecessary risk to patients and alleviates the burden on the medical system.
In responders, the results are remarkable and include improvements in both depression and cognition. These outcomes are promising, but knowing the full impact requires understanding the long-term behaviour of the effects. Importantly, these improvements were obtained with slightly more than a total of one hour of iTBS exposure across 4 weeks, approximately ten times less than would be required for an rTMS treatment. Future work should more rigorously investigate these findings through randomised controlled trials, including assessment of long-term cognitive outcomes and risk of dementia.
Competing interests
PW: No competing interests to report in relation to this work. SK: Research support from the Brain and Behaviour Foundation, the National Institute on Ageing, the BrightFocus Foundation, Brain Canada, the Canadian Institute of Health Research, the Canadian Consortium on Neurodegeneration in Ageing, the Centre for Ageing and Brain Health Innovation, the Centre for Addiction and Mental Health, the University of Toronto, the Ontario Ministry of Health, the Weston Brain Institute, the Slaight Family Foundation, and the Hilary and Galen Weston Foundation and equipment support from Soterix Medical. He is also a site investigator for a trial funded by Bristol Myers Squibb.